Skip to main content

Table 3 Unadjusted and adjusted hazard ratios of the impact of MMR immunophenotype on overall survival in I-type tumors, PB-type tumors, and the entire cohort

From: Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma

  Intestinal type Pancreatobiliary type All
n (events) Unadjusted Adjusted n (events) Unadjusted Adjusted n (events) Unadjusted Adjusted
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Age
 Continuous 63 (39) 1.01 (0.98–1.05) – 109 (98) 0.99 (0.97–1.02) – 172 (137) 1.01 (0.99–1.03) –
Gender
 Female 35 (17) 1.00 1.00 51 (45) 1.00 – 86 (62) 1.00 –
34 (16)*
 Male 28 (22) 2.01 (1.05–3.84) 1.60 (0.79–3.24) 58 (53) 1.15 (0.77–1.71)   86 (75) 1.40 (1.00–1.97)  
  27 (21)*         
Tumor origin
 Intestinal   – –   – – 63 (39) 1.00 1.00
        61 (37)*   
 Pancreatobiliary type   – –   – – 109 (98) 2.54 (1.73–3.73) 1.61 (1.01–2.55)
        108 (98)*   
Tumor size
 Continuous 63 (39) 1.00 (0.98–1.02) – 109 (98) 1.04 (1.02–1.06) 1.02 (1.00–1.04) 172 (137) 1.02 (1.00–1.03) 1.01 (0.99–2.55)
     108 (98)*    169 (135)*   
T-stage
 T1–T2 16 (8) 1.00 – 15 (10) 1.00 1.00 31 (18) 1.00 1.00
     14 (10)*    28 (16)*   
 T3–T4 47 (31) 1.72 (0.79–3.74)   94 (88) 2.47 (1.28–4.77) 1.06 (0.50–2.27) 141 (119) 2.34 (1.42–3.86) 1.21 (0.66–2.21)
     94 (88)*    141 (119)*   
N-stage
 N0 35 (19) 1.00 – 32 (25) 1.00 1.00 67 (44) 1.00 1.00
     31 (25)*    64 (42)*   
 N1–2 28 (20) 1.56 (0.83–2.94)   77 (73) 2.23 (1.41–3.54) 2.06 (1.16–3.65) 105 (93) 2.19 (1.52–3.16) 1.34 (0.88–2.05)
     77 (73)*    105 (93)*   
Differentiation grade
 Well-moderate 31 (17) 1.00 – 42 (32) 1.00 1.00 73 (49) 1.00 1.00
     41 (32)*    71 (48)*   
 Poor 32 (22) 1.70 (0.90–3.21)   67 (66) 2.63 (1.70–4.09) 2.05 (1.24–3.39) 99 (88) 2.24 (1.57–3.18) 1.65 (1.09–2.48)
     67 (66)*    98 (87)*   
Involved margins, status
 R0 18 (5) 1.00 1.00 7 (5) 1.00 – 25 (10) 1.00 1.00
  17 (4)*       23 (9)*   
 R1 and Rx 45 (34) 3.30 (1.29–8.46) 2.89 (0.94–8.85) 102 (93) 2.42 (0.98–6.00)   147 (127) 3.57 (1.87–6.83) 2.23 (1.10–4.51)
  44 (33)*       146 (126)*   
Lymphatic growth
 Absent 28 (10) 1.00 1.00 35 (27) 1.00 1.00 63 (37) 1.00 1.00
  28 (10)*    34 (27)*    62 (37)*   
 Present 35 (29) 3.94 (1.90–8.18) 1.77 (0.77–4.09) 74 (71) 1.78 (1.13–2.79) 1.09 (0.65–1.83) 109 (100) 2.54 (1.73–3.73) 1.33 (0.85–2.07)
  33 (27)*    74 (71)*    107 (98)*   
Vascular growth
 Absent 58 (34) 1.00 1.00 73 (62) 1.00 1.00 131 (96) 1.00 1.00
  56 (32)*    72 (62)*    128 (94)*   
 Present 5 (5) 6.68 (2.40–18.62) 4.69 (1.48–14.84) 36 (36) 2.47 (1.61–3.80) 2.20 (1.38–3.52) 41 (41) 3.49 (2.37–5.15) 2.18 (1.43–3.34)
  5 (5)*    36 (36)*    41 (41)*   
Perineural growth
 Absent 43 (21) 1.00 1.00 25 (19) 1.00 1.00 68 (40) 1.00 1.00
  42 (20)*    24 (19)*    66 (39)*   
 Present 20 (18) 2.81 (1.48–5.35) 1.36 (0.57–3.21) 84 (79) 1.96 (1.18–3.25) 0.88 (0.48–1.61) 104 (97) 2.96 (2.02–4.43) 1.06 (0.66–1.71)
  19 (17)*    84 (79)*    103 (96)*   
Growth in peripancreatic fat
 Absent 42 (20) 1.00 1.00 25 (20) 1.00 1.00 67 (40) 1.00 1.00
  40 (18)*    24 (20)*    64 (38)*   
 Present 21 (19) 3.65 (1.86–7.16) 1.78 (0.73–4.33) 84 (78) 1.75 (1.06–2.88) 0.99 (0.56–1.77) 105 (97) 3.00 (2.03–4.43) 1.37 (0.85–2.22)
  21 (19)*    84 (78)*    105 (97)*   
Adjuvant treatment
 None 45 (30) 1.00 – 50 (44) 1.00 – 95 (74) 1.00 –
 Any 18 (9) 0.69 (0.33–1.47)   59 (54) 0.96 (0.64–1.42)   77 (63) 1.09 (0.78–1–53)  
MMR
 pMMR 49 (34) 1.00 1.00 101 (93) 1.00 1.00 150 (127) 1.00 1.00
  49 (34)*    101 (93)*    150 (127)*   
 dMMR 12 (3) 0.20 (0.06–0.68) 0.36 (0.09–1.42) 7 (5) 0.57 (0.23–1.42) 1.24 (0.46–3.37) 19 (8) 0.28 (0.13–0.57) 0.52 (0.23–1.19)
  12 (3)*    7 (5)*    19 (8)*   
  1. Italic values indicate significance at p < 0.05
  2. *Number and events for the adjusted analysis
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us